Highlights 

  • Silexion completes toxicology studies for next-generation siRNA therapy SIL204 
  • Therapy targets mutated KRAS, a key driver in pancreatic cancer 
  • Preclinical results show meaningful cancer-growth inhibition 
  • Phase 2/3 trial expected to begin in Q2 2026 

Silexion Therapeutics Corp. (NASDAQ:SLXN) has announced an important milestone with the successful completion of toxicology studies for SIL204, a next-generation RNA-silencing therapy developed to target mutated KRAS oncogenes. Pancreatic cancer continues to be one of the deadliest malignancies, with limited treatment choices and exceptionally poor survival rates. Since KRAS mutations are among the most pervasive drivers of aggressive tumors, therapies capable of disrupting mutated KRAS expression represent a high-value clinical direction. 

SIL204 has been engineered to inhibit the production of mutated KRAS proteins by using enhanced siRNA design principles. Early research suggests the therapy effectively suppresses tumor cell proliferation in multiple KRAS-mutated pancreatic cancer models. These findings build on years of groundwork in KRAS-focused drug development, an area long considered challenging due to the mutation’s role in cancer cell signaling. 

Preclinical and Toxicology Data Set the Stage for Global Submissions 

According to Silexion, preclinical models demonstrated encouraging anti-tumor activity, particularly when SIL204 was administered systemically and delivered to pancreatic cancer sites. The recently completed toxicology studies showed no systemic organ toxicity, an important requirement before advancing into human trials. This result enables the company to proceed with regulatory filings in Israel and Germany, two regions where Silexion intends to initiate the next stages of clinical development. 

The company has prior experience with KRAS-targeting technologies through its first-generation product, LODER (Local Drug EluteR). In a Phase 2a study, LODER displayed a positive trend when combined with chemotherapy. SIL204 represents a significant evolution of that platform, now featuring enhanced delivery chemistry and improved stability that aims to expand therapeutic reach beyond localized tumors. 

Phase 2/3 Trial Planned for Q2 2026 With Combined Dosing Strategy 

Silexion is now preparing for a Phase 2/3 clinical trial expected to begin in Q2, 2026. The study will explore a hybrid regimen that integrates intratumoral and systemic dosing—an approach designed to maximize therapeutic exposure while maintaining patient safety. This integrated method may offer new possibilities for treating locally advanced pancreatic cancer, where traditional therapies often fall short. 

Conclusion 

The completion of toxicology studies marks a major advancement for Silexion as it prepares SIL204 for late-stage trials. With its refined siRNA architecture and encouraging preclinical performance, SIL204 has the potential to contribute meaningfully to pancreatic cancer treatment research. As the company moves into regulatory review and clinical evaluation, stakeholders will be watching closely to see how SIL204 performs in human studies.  

Silexion Therapeutics’ shares closed at USD 2.89, marking an 18.44% increase from the prior session. 

Also read - GE HealthCare (NASDAQ:GEHC): New Pristina Recon DL Technology Enhances Mammography Imaging